openPR Logo
Press release

Global Rheumatoid Arthritis Drug Market Outlook 2022 Report

05-07-2018 05:59 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Rheumatoid Arthritis Drug Market Outlook 2022 Report

“Global Rheumatoid Arthritis Drug Market Outlook 2022” report highlights:

* Classification and Molecular Mechanism of Rheumatoid Arthritis Drugs
* Synthetic DMARDs as Rheumatoid Arthritis Drug
* Biological Agents as Rheumatoid Arthritis Drug
* Global Market of Rheumatoid Arthritis Drug
* Global Tendencies in Use of Antirheumatics
* Global Rheumatoid Arthritis Drug Market Future Prospect

Download Report Sample Weblink:

https://www.kuickresearch.com/report-global-rheumatoid-arthritis-drug-market-outlook-2022.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

Antirheumatoids: Call of Rheumatoid Arthritis
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis

Molecular Mechanism of Antirheumatoids
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 and IL-6 Blockers

Classification of Rheumatoid Arthritis Drugs
3.1 Traditional Classification of Rheumatoid Arthritis Drugs
3.2 New Proposed Classification of DMARDs

Synthetic DMARDs as Rheumatoid Arthritis Drug
4.1 Methotrexate (MTX)
4.2 Sulfasalazine (SSZ)
4.3 Leflunomide
4.4 Hydroxychloroquine (HCQ)

Biological Agents as Rheumatoid Arthritis Drug
5.1 Cytokine Inhibitors
5.1.1 Etanercept (Enbrel)
5.1.2 Infliximab (Remicade)
5.1.3 Adalimumab (Humira)
5.1.4 Golimumab (Simponi)
5.1.5 Certolizumab pegol (Cimzia)
5.2 Interleukin 1 and Interleukin 6 Inhibitors
5.2.1 Anakinra (Kineret)
5.2.2 Tocilizumab (RoActerma)
5.3 T-Cell and B-Cell Inhibitors
5.3.1 Abatacept (Orencia)
5.3.2 Rituximab (Mabthera)

Global Prevalence of Rheumatoid Arthritis
6.1 US
6.2 Europe
6.3 Canada
6.4 Asia

Global Tendencies in Use of Antirheumatics
7.1 Trail from Conventional to Biological DMARDs
7.2 Global Trends of Antirheumatic Prescription

Global Market of Rheumatoid Arthritis Drug
8.1 Market Overview of DMARDs
8.2 Market of Biosimilar DMARDs
8.3 Top Leading DMARDs by Revenues (2015 and 2022)
8.3.1 Humira (Adalimumab)
8.3.2 Enbrel (Etanercept)
8.3.3 Remicade
8.3.4 Simponi
8.3.5 Otezla (Celgene)

Global Rheumatoid Arthritis Drug Market Dynamics
9.1 Accelerative Parameters
9.2 Challenges

Global Rheumatoid Arthritis Drug Market Future Prospect

Competitive Landscape
11.1 Abbvie
11.2 Biogen Idec
11.3 Bristol-Myers Squibb
11.4 Celgene
11.5 Celltrion
11.6 JandJ
11.7 MedImmune
11.8 Merck
11.9 Novartis
11.10 Takeda

Figure 1-1: Representation of the Disease Progression in Rheumatoid Arthritis
Figure 2-1: Mechanism of Action of Anti-TNF in Rheumatoid Arthritis Treatment
Figure 3-1: Classified Antirheumatic Drugs Pattern in Course of Treatment
Figure 3-2: Demonstration of New Nomenclature for Antirheumatic Drugs
Figure 4-1: Structure of Several Synthetic Antirheumatic DMARDs
Figure 5-1: ACR Response Rate of Infliximab vs. Biosimilar CT-P13
Figure 5-2: Immunoglobulin Structures of the TNF Agonists including all Five Classes
Figure 6-1: Worldwide Prevalence of Rheumatoid Arthritis
Figure 6-2: Percentage of Rheumatoid Arthritis by Gender in US
Figure 6-3: Prevalence of Rheumatoid Arthritis over Ethnicity
Figure 6-4: Incidence of Rheumatoid Arthritis with Increasing Age
Figure 6-5: Illustration of Upcoming Risk of RA in US
Figure 6-6: Illustration of Percentage of Prevalence of Rheumatic Arthritis
Figure 6-7: Projected Number of Individuals with Rheumatism in Canada
Figure 7-1: Traditional Mode of Rheumatoid Arthritis Treatment
Figure 7-2: Illustration of Changes in Use of DMARDs after MTX
Figure 7-3: US: Percentage of Type of DMARDs Used for RA in 2013
Figure 8-1: Global - Rheumatoid Arthritis Drug Sales (US$ Billion), 2015-2022
Figure 8-2: Patent Expiration of Major Antirheumatic Drugs under Biologics in EU and US
Figure 8-3: Global - Top Rheumatoid Arthritis Drugs by Revenue from 2015 and 2022
Figure 8-4: Global andndash; Share of Top Rheumatoid Arthritis Drugs in Market (%),2022
Figure 8-5: Global - Humira Sales (US$ Billion), 2011-2015 and 2022
Figure 8-6: Global - Enbrel Sales (US$ Billion), 2015- 2016 and 2022
Figure 8-7: Global andndash; Remicade Sales (US$ Billion), 2015 and 2022
Figure 8-8: Global Percentage of Simponi Sale Revenues by Region (2015-2022) (Billions)
Figure 8-9: Global andndash; Simponi Sales (US$ Billion), 2015 and 2022
Figure 8-10: Global - Otezela Sales (US$ Billion) 2015 and 2022
Figure 9-1: Major Driving Forces of Antirheumatics Drug Market
Figure 9-2: Increasing Market Size of Biosimilars Worldwide
Figure 9-3: Major Challenges faced by Antirheumatics Market
Figure 9-4: Average Annual Treatment Cost of Humira, Enbrel and Remicade (US$), 2014
Figure 10-1: Global - Rheumatoid Arthritis Drug Market by Drug Class (TNF Inhibitors, JAK Inhibitors and Others) 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Rheumatoid Arthritis Drug Market Outlook 2022 Report here

News-ID: 1040643 • Views: 200

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Arthritis

Treatment Options for Arthritis Patients
Arthritis can show itself as a dull ache, a sharp pain or a grip on your joints. It is the leading cause of pain and disability worldwide. It is important to know what the disease is, its causes and treatment options. Causes Arthritis can be the result of different causes, such as – • Age related wear and tear of articular cartilage • Injury that leads to degenerative arthritis • Abnormal metabolism that leads to gout and
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards Rheumatoid Arthritis 1.2 Obtainable Treatment for Rheumatoid Arthritis Molecular Mechanism of Antirheumatoids 2.1 Purpose of DMARDs in Rheumatoid Arthritis 2.2 Role of Biological Agents in Rheumatoid Arthritis 2.2.1 TNF- Inhibitors 2.2.2 Interleukin -1 and IL-6 Blockers Classification of Rheumatoid Arthritis Drugs 3.1
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the
Worldwide Arthritis - EpiCast Report: Rheumatoid Arthritis - Epidemiology Foreca …
"EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2025" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- ** Summary Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the bodys immune system attacks the lining of the joints, known as
Arthritis Foundation Expands Annual Juvenile Arthritis Conference to Two Locatio …
Kicking off during Juvenile Arthritis Awareness Month, the Arthritis Foundation is hosting two Juvenile Arthritis Conferences over the next five weeks. Almost 2,000 children and family members – a record attendance number – will gather in Phoenix, July 14–17, and Philadelphia, Aug. 11–14, to learn more about coping with their disease and meet other families who share their journey. Arthritis afflicts nearly 300,000 children in the United States – and